231 related articles for article (PubMed ID: 31370977)
1. A comparison of buprenorphine and psychosocial treatment outcomes in psychosocial and medical settings.
Presnall NJ; Wolf DAPS; Brown DS; Beeler-Stinn S; Grucza RA
J Subst Abuse Treat; 2019 Sep; 104():135-143. PubMed ID: 31370977
[TBL] [Abstract][Full Text] [Related]
2. Buprenorphine prescribing for opioid use disorder in medical practices: can office-based out-patient care address the opiate crisis in the United States?
Rhee TG; Rosenheck RA
Addiction; 2019 Nov; 114(11):1992-1999. PubMed ID: 31307111
[TBL] [Abstract][Full Text] [Related]
3. Polysubstance use and association with opioid use disorder treatment in the US Veterans Health Administration.
Lin LA; Bohnert ASB; Blow FC; Gordon AJ; Ignacio RV; Kim HM; Ilgen MA
Addiction; 2021 Jan; 116(1):96-104. PubMed ID: 32428386
[TBL] [Abstract][Full Text] [Related]
4. Psychosocial and behavioral therapy in conjunction with medication for opioid use disorder: Patterns, predictors, and association with buprenorphine treatment outcomes.
Samples H; Williams AR; Crystal S; Olfson M
J Subst Abuse Treat; 2022 Aug; 139():108774. PubMed ID: 35337716
[TBL] [Abstract][Full Text] [Related]
5. A comparison of adherence, outcomes, and costs among opioid use disorder Medicaid patients treated with buprenorphine and methadone: A view from the payer perspective.
Kinsky S; Houck PR; Mayes K; Loveland D; Daley D; Schuster JM
J Subst Abuse Treat; 2019 Sep; 104():15-21. PubMed ID: 31370980
[TBL] [Abstract][Full Text] [Related]
6. Differential adoption of opioid agonist treatments in detoxification and outpatient settings.
Dunn KE; Huhn AS; Strain EC
J Subst Abuse Treat; 2019 Dec; 107():24-28. PubMed ID: 31757261
[TBL] [Abstract][Full Text] [Related]
7. Comparative Effectiveness Associated With Buprenorphine and Naltrexone in Opioid Use Disorder and Cooccurring Polysubstance Use.
Xu KY; Mintz CM; Presnall N; Bierut LJ; Grucza RA
JAMA Netw Open; 2022 May; 5(5):e2211363. PubMed ID: 35536575
[TBL] [Abstract][Full Text] [Related]
8. Association between trajectories of buprenorphine treatment and emergency department and in-patient utilization.
Lo-Ciganic WH; Gellad WF; Gordon AJ; Cochran G; Zemaitis MA; Cathers T; Kelley D; Donohue JM
Addiction; 2016 May; 111(5):892-902. PubMed ID: 26662858
[TBL] [Abstract][Full Text] [Related]
9. Association Between Hospital Adoption of an Emergency Department Treatment Pathway for Opioid Use Disorder and Patient Initiation of Buprenorphine After Discharge.
Solomon KT; O'Connor J; Gibbons JB; Kilaru AS; Feder KA; Xue L; Saloner B; Stuart EA; Cole ES; Hulsey E; Meisel Z; Patel E; Donohue JM
JAMA Health Forum; 2023 Mar; 4(3):e230245. PubMed ID: 36961457
[TBL] [Abstract][Full Text] [Related]
10. Association between treatment setting and outcomes among oregon medicaid patients with opioid use disorder: a retrospective cohort study.
Hartung DM; Markwardt S; Johnston K; Geddes J; Baker R; Leichtling G; Hildebran C; Chan B; Cook RR; McCarty D; Ghitza U; Korthuis PT
Addict Sci Clin Pract; 2022 Aug; 17(1):45. PubMed ID: 35986384
[TBL] [Abstract][Full Text] [Related]
11. Treatment setting and buprenorphine discontinuation: an analysis of multi-state insurance claims.
Xu KY; Gertner AK; Greenfield SF; Williams AR; Grucza RA
Addict Sci Clin Pract; 2024 Mar; 19(1):17. PubMed ID: 38493109
[TBL] [Abstract][Full Text] [Related]
12. Risk factors for discontinuation of buprenorphine treatment for opioid use disorders in a multi-state sample of Medicaid enrollees.
Samples H; Williams AR; Olfson M; Crystal S
J Subst Abuse Treat; 2018 Dec; 95():9-17. PubMed ID: 30352671
[TBL] [Abstract][Full Text] [Related]
13. Patient Barriers and Facilitators to Medications for Opioid Use Disorder in Primary Care.
Tofighi B; Williams AR; Chemi C; Suhail-Sindhu S; Dickson V; Lee JD
Subst Use Misuse; 2019; 54(14):2409-2419. PubMed ID: 31429351
[No Abstract] [Full Text] [Related]
14. Peer recovery coaches in general medical settings: Changes in utilization, treatment engagement, and opioid use.
Magidson JF; Regan S; Powell E; Jack HE; Herman GE; Zaro C; Kane MT; Wakeman SE
J Subst Abuse Treat; 2021 Mar; 122():108248. PubMed ID: 33509420
[TBL] [Abstract][Full Text] [Related]
15. Association of polysubstance use disorder with treatment quality among Medicaid beneficiaries with opioid use disorder.
Smart R; Kim JY; Kennedy S; Tang L; Allen L; Crane D; Mack A; Mohamoud S; Pauly N; Perez R; Donohue J
J Subst Abuse Treat; 2023 Jan; 144():108921. PubMed ID: 36327615
[TBL] [Abstract][Full Text] [Related]
16. Long-term retention in Office Based Opioid Treatment with buprenorphine.
Weinstein ZM; Kim HW; Cheng DM; Quinn E; Hui D; Labelle CT; Drainoni ML; Bachman SS; Samet JH
J Subst Abuse Treat; 2017 Mar; 74():65-70. PubMed ID: 28132702
[TBL] [Abstract][Full Text] [Related]
17. Association of Buprenorphine-Waivered Physician Supply With Buprenorphine Treatment Use and Prescription Opioid Use in Medicaid Enrollees.
Wen H; Hockenberry JM; Pollack HA
JAMA Netw Open; 2018 Sep; 1(5):e182943. PubMed ID: 30646185
[TBL] [Abstract][Full Text] [Related]
18. Office-Based Opioid Treatment with Buprenorphine (OBOT-B): Statewide Implementation of the Massachusetts Collaborative Care Model in Community Health Centers.
LaBelle CT; Han SC; Bergeron A; Samet JH
J Subst Abuse Treat; 2016 Jan; 60():6-13. PubMed ID: 26233698
[TBL] [Abstract][Full Text] [Related]
19. Barriers to accessing treatment for pregnant women with opioid use disorder in Appalachian states.
Patrick SW; Buntin MB; Martin PR; Scott TA; Dupont W; Richards M; Cooper WO
Subst Abus; 2019; 40(3):356-362. PubMed ID: 29949454
[No Abstract] [Full Text] [Related]
20. The effect of Medicaid expansion on use of opioid agonist treatment and the role of provider capacity constraints.
Gertner AK; Robertson AG; Jones H; Powell BJ; Silberman P; Domino ME
Health Serv Res; 2020 Jun; 55(3):383-392. PubMed ID: 32166761
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]